Program
apatinib
Also written as “Apatinib”, “Rivoceranib” and “Apatinib Mesylate”.
Its studies are mostly in Stomach Neoplasms · Ovarian Neoplasms · Neoplasms · Carcinoma, Hepatocellular · Carcinoma, Non-Small-Cell Lung, led by 8 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Jiangsu HengRui Medicine | 344 open or running | phase 3since Jan 13, 2012 | Aug 30, 2010 | none ahead |
| Elevar Therapeutics | 70 open or running | phase 3since Jan 24, 2017 | Dec 18, 2011 | none ahead |
| Bukwang Pharmaceutical | 10 open or running | phase 1since Feb 26, 2016 | Feb 26, 2016 | none ahead |
| GrandPharma (China) | 11 open or running | phase 2since Aug 13, 2025 | Aug 13, 2025 | Dec 30, 2027phase 2 · NCT07334483 |
| Guangzhou Virotech Pharmaceutical | 11 open or running | phase 3since May 8, 2026 | May 8, 2026 | Dec 31, 2028phase 3 · NCT07589244 |
| Hansoh Pharmaceutical Group | 11 open or running | phase 1since Jan 7, 2025 | Jan 7, 2025 | none ahead |
| HRYZ Biotech | 11 open or running | early phase 1since Aug 26, 2019 | Aug 26, 2019 | none ahead |
| Qilu Pharmaceutical | 10 open or running | phase 2since Aug 14, 2017 | Aug 14, 2017 | none ahead |
Also a collaborator on its studies: bukwang-pharmaceutical-co-ltd.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 32 studies since Aug 30, 2010.
- Apr 8, 2020Phase 1 study in Healthy SubjectsJiangsu HengRui Medicine · NCT04341090 · 42 enrolled · China
- Apr 9, 2020Phase 3 study in Stomach NeoplasmsJiangsu HengRui Medicine · NCT04342910 · 550 planned · China
- May 6, 2020Phase 2 study in Ovarian NeoplasmsJiangsu HengRui Medicine · NCT04383977 · 54 enrolled
- May 13, 2020Phase 1 study in NSCLCJiangsu HengRui Medicine · NCT04390984 · 22 enrolled · China
- Jun 1, 20202 phase 1 studiesJiangsu HengRui Medicine · NCT04414852, NCT04457180
- Aug 16, 2020Phase 2 study in Ovarian NeoplasmsJiangsu HengRui Medicine · NCT04517357 · 100 enrolled · China
- Nov 19, 2020Phase 3 study in Carcinoma, HepatocellularJiangsu HengRui Medicine · NCT04639180 · 687 enrolled · China
- Apr 26, 2021Phase 2 study in Metastatic Castration Resistant Prostate CancerJiangsu HengRui Medicine · NCT04869488 · 93 enrolled · China
- Jul 15, 2021Phase 3 study in Advanced Hepatocellular Carcinoma (HCC)Jiangsu HengRui Medicine · NCT04985136 · 1 enrolled · China
- Mar 10, 2022Phase 1 study in HealthyElevar Therapeutics · NCT05287360 · 60 enrolled · United States
- Apr 2, 2022Phase 3 study in Carcinoma, HepatocellularJiangsu HengRui Medicine · NCT05320692 · 423 enrolled · China
- Jan 7, 2025Hansoh Pharmaceutical Group's first study: phase 1 study in Ovarian NeoplasmsNew to Hansoh Pharmaceutical GroupHansoh Pharmaceutical Group · NCT06769425 · 157 planned · China
- Aug 13, 2025GrandPharma (China)'s first study: phase 2 study in HCCNew to GrandPharma (China)GrandPharma (China) · NCT07334483 · 120 planned · China
- May 8, 2026Guangzhou Virotech Pharmaceutical's first study: phase 3 study in HCCNew to Guangzhou Virotech PharmaceuticalGuangzhou Virotech Pharmaceutical · NCT07589244 · 66 planned · China
Ahead
- Dec 30, 2027Primary completion: phase 2 study in HCCGrandPharma (China) · NCT07334483
- Dec 31, 2028Primary completion: phase 3 study in HCCGuangzhou Virotech Pharmaceutical · NCT07589244
TargetBeta
“Vascular endothelial growth factor receptor 2 inhibitor”ChEMBL 37, by rule
Other programs on KDR
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| lenvatinibrule | Eisai | phase 4 | 81 |
| nintedanibrule | Boehringer Ingelheim | phase 4 | 76 |
| regorafenibrule | Bayer | phase 4 | 40 |
| cabozantinibrule | Exelixis | phase 4 | 36 |
| Ramucirumabrule | Eli Lilly | phase 3 | 58 |
| Axitinibrule | Pfizer | phase 3 | 45 |
| anlotinibrule | Sino Biopharmaceutical | phase 3 | 40 |
| vorolanibrule | Betta Pharmaceuticals | phase 3 | 24 |
| zanzalintinibrule | Exelixis | phase 3 | 17 |
| chiauranibrule | Chipscreen Biosciences | phase 3 | 15 |
| Aurora B/VEGFR/FGFR Inhibitor AL8326rule | advenchen-laboratories-nanjing-ltd | phase 3 | 8 |
| AXL/FLT3/VEGFR2 Inhibitor KC1036rule | beijing-konruns-pharmaceutical-co-ltd | phase 3 | 7 |
Studies
All 47 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07589244HCC · China | 3 | Recruiting | Guangzhou Virotech Pharmaceutical | Dec 31, 2028 | 66 |
| NCT07334483HCC · China | 2 | Recruiting | GrandPharma (China) | Dec 30, 2027 | 120 |
| NCT06769425Ovarian Neoplasms · China | 1 | Recruiting | Hansoh Pharmaceutical Group | May 7, 2026 | 157 |
| NCT05320692Carcinoma, Hepatocellular · China | 3 | Active, not recruiting | Jiangsu HengRui Medicine | Jul 30, 2026 | 423 |
| NCT05287360Healthy · United States | 1 | Completed | Elevar Therapeutics | Mar 16, 2022 | 60 |
| NCT04985136Advanced Hepatocellular Carcinoma (HCC) · China | 3 | Terminated | Jiangsu HengRui Medicine | Dec 29, 2021 | 1 |
| NCT04869488Metastatic Castration Resistant Prostate Cancer · China | 2 | Completed | Jiangsu HengRui Medicine | Feb 14, 2023 | 93 |
| NCT04639180Carcinoma, Hepatocellular · China | 3 | Active, not recruiting | Jiangsu HengRui Medicine | Jul 31, 2026 | 687 |
| NCT04517357Ovarian Neoplasms · China | 2 | Completed | Jiangsu HengRui Medicine | Nov 30, 2023 | 100 |
| NCT04457180Advanced Solid Tumor · China | 1 | Completed | Jiangsu HengRui Medicine | May 20, 2021 | 18 |
| NCT04414852Subjects With Impaired Renal Function and Healthy Subjects | 1 | UNKNOWN | Jiangsu HengRui Medicine | Jan 15, 2021 | 24 |
| NCT04390984NSCLC · China | 1 | UNKNOWN | Jiangsu HengRui Medicine | Feb 2021 | 22 |
| NCT04383977Ovarian Neoplasms | 2 | UNKNOWN | Jiangsu HengRui Medicine | Dec 2020 | 54 |
| NCT04342910Stomach Neoplasms · China | 3 | Recruiting | Jiangsu HengRui Medicine | Apr 1, 2026 | 550 |
| NCT04341090Healthy Subjects · China | 1 | Completed | Jiangsu HengRui Medicine | Jul 6, 2020 | 42 |
| NCT04335006Breast Neoplasms · China | 3 | Terminated | Jiangsu HengRui Medicine | Apr 14, 2023 | 80 |
| NCT04322552Advanced Solid Tumor · China | 1 | Completed | Jiangsu HengRui Medicine | Apr 3, 2021 | 18 |
| NCT04296370Treatment in HER2-negative Metastatic Breast Cancer Patients With Germline BRCA Mutation · China | 3 | Recruiting | Jiangsu HengRui Medicine | Jun 30, 2022 | 474 |
| NCT04229615Ovarian Neoplasms · China | 3 | UNKNOWN | Jiangsu HengRui Medicine | Jun 30, 2023 | 690 |
| NCT04203485PD-L1 Positive Non-small Cell Lung Cancer | 3 | UNKNOWN | Jiangsu HengRui Medicine | Mar 31, 2022 | 762 |
| NCT04119453Carcinoma, Adenoid Cystic · United States, South Korea | 2 | Terminated | Elevar Therapeutics | Jun 28, 2023 | 80 |
| NCT04074564Sarcoma · China | Early 1 | Recruiting | HRYZ Biotech | Aug 7, 2024 | 60 |
| NCT04073615Colorectal Neoplasms · United States | 1 | Terminated | Elevar Therapeutics | May 31, 2023 | 29 |
| NCT04000295Ovarian Neoplasms · China | 3 | UNKNOWN | Jiangsu HengRui Medicine | Jan 2021 | 280 |
| NCT03945604Triple Negative Breast Neoplasms · China | 1 | Completed | Jiangsu HengRui Medicine | Feb 9, 2021 | 32 |
| NCT03711279Sarcoma · China | 2 | Terminated | Jiangsu HengRui Medicine | Jun 21, 2021 | 99 |
| NCT03707028Stomach Neoplasms · Korea, Republic of | 2 | Terminated | Elevar Therapeutics | Aug 24, 2021 | 12 |
| NCT03491631Neoplasms · China | 1 | UNKNOWN | Jiangsu HengRui Medicine | Jun 2023 | 23 |
| NCT03472365Stomach Neoplasms · China | 2 | Completed | Jiangsu HengRui Medicine | Nov 25, 2020 | 67 |
| NCT03463876Carcinoma, Hepatocellular · China | 2 | Completed | Jiangsu HengRui Medicine | Mar 10, 2021 | 190 |
| NCT03396211Neoplasms · United States | 1 | Completed | Elevar Therapeutics | Oct 28, 2020 | 30 |
| NCT03267654Carcinoma, Non-Small-Cell Lung · China | 2 | UNKNOWN | Qilu Pharmaceutical | Oct 20, 2020 | 100 |
| NCT03245307Cytochrome P450 Interaction · China | 1 | UNKNOWN | Jiangsu HengRui Medicine | Apr 30, 2018 | 20 |
| NCT03075462Ovarian Neoplasms · China | 1 | Completed | Jiangsu HengRui Medicine | Aug 22, 2021 | 98 |
| NCT03042611Stomach Neoplasms · United States, France, Germany and more | 3 | Completed | Elevar Therapeutics | Feb 15, 2019 | 460 |
| NCT03026881Recurrence · China | 1 | UNKNOWN | Jiangsu HengRui Medicine | Apr 2018 | 24 |
| NCT02836171Neoplasms · China | 1 | Completed | Jiangsu HengRui Medicine | Feb 2017 | 20 |
| NCT02836821Neoplasms · China | 1 | Completed | Jiangsu HengRui Medicine | Feb 2017 | 20 |
| NCT02764268Stomach Neoplasms · China | – | Completed | Jiangsu HengRui Medicine | Dec 10, 2018 | 60 |
| NCT02711969Stomach Neoplasms · Korea, Republic of | 1 | Completed | Bukwang Pharmaceutical | Nov 2016 | 6 |
| NCT02332512Carcinoma, Non-Small-Cell Lung · China | 3 | UNKNOWN | Jiangsu HengRui Medicine | Aug 2017 | 417 |
| NCT02329860Carcinoma, Hepatocellular · China | 3 | Completed | Jiangsu HengRui Medicine | Dec 15, 2017 | 400 |
| NCT01531777Colorectal Neoplasms · China | 2 | Completed | Jiangsu HengRui Medicine | Nov 2014 | 40 |
| NCT01512745Stomach Neoplasms · China | 3 | Completed | Jiangsu HengRui Medicine | May 2013 | 267 |
| NCT01497704Neoplasms · United States, Korea, Republic of | 2 | Completed | Elevar Therapeutics | Feb 2015 | 55 |
| NCT01270386Carcinoma, Non-Small-Cell Lung · China | 2 | Completed | Jiangsu HengRui Medicine | Jul 2011 | 136 |
| NCT01192971Neoplasms · China | 2 | Completed | Jiangsu HengRui Medicine | Jul 2013 | 121 |
How it is read
Names in the registry
- “Apatinib”, 13 entries
- “Rivoceranib”, 5 entries
- “Apatinib Mesylate”, 5 entries
- “apatinib”, 3 entries
- “Fluzoparib+Apatinib”, 2 entries
Conditions, from the studies’ own filings
- Stomach Neoplasms, 8 studies
- Ovarian Neoplasms, 6 studies
- Neoplasms, 6 studies
- Carcinoma, Hepatocellular, 5 studies
- Carcinoma, Non-Small-Cell Lung, 4 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.